DMAC News and Press, DiaMedica Therapeutics Inc. From 07/02/21

Matteo Colombo/DigitalVision via Getty Images S&P 500 Health Care Sector Index rose ~2.0% over the week to outpace the ~1.7% gain in the S&P 500 as gene editing companies rallied after Intellia (NTLA) and Regeneron (REGN) showed promise in the CRISPR technology with fir...

Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite (AMST) +22%.Global Internet of Peopl...

Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifescience...

naphtalina/iStock via Getty Images Biggest. Order. Ever. United Airlines (UAL) made headlines Tuesday by announcing the largest aircraft purchase in the company's history. Jefferies (JEF) and Herman Miller (MLHR) both moved in pre-market trading after the release of earnings news. Cerevel The...

DiaMedica Therapeutics DMAC -27% after announcing mixed results for kidney disease therapy in mid-stage study.Celcuity CELC -18% after raises $56M capital via equity offering.Purple Innovation PRPL -12% after lowering Q2 guidance due to production challenge.ReSha...

Diamedica Therapeutics (DMAC) has lost ~12.1% in the pre-market after the company announced clinically meaningful results for two cohorts from a Phase 2 trial for DM199 in chronic kidney disease ((CKD)).The trial is designed to evaluate the effect of DM199, a recombinant (...

Results Affirm Biological Activity, Safety and Tolerability of DM199 Consistent with Porcine KLK1 Product in Asia Early Data Indicate Statistically and Clinically Significant Reduction in UACR seen in IgA Nephropathy and Hypertensive African Americans – a Key Ri...

DiaMedica produced decent stroke data last year for DM199. The company does not have a lot of cash. DMAC presents a speculative investment opportunity. For further details see: DiaMedica: Undercovered Stroke Drug Company With Decent Data

DiaMedica Therapeutics (DMAC) announces that the U.S. FDA has accepted the company’s Investigational New Drug ((IND)) application for a Phase 2/3 trial in Acute Ischemic Stroke ((AIS)) patients.The company said that it plans to proceed with a pivotal Phase 2/3 study of DM199 ...

Initiating ReMEDy2 – Pivotal Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseas...